grant
Mitigation of Cardiovascular Damage
Organization COLUMBIA UNIVERSITY HEALTH SCIENCESLocation NEW YORK, UNITED STATESPosted 26 Aug 2025Deadline 30 Jun 2030
NIHUS FederalResearch GrantFY2025ACE InhibitorsActive Follow-upAcuteAddressAngiotensin I-Converting Enzyme InhibitorsAngiotensin-Converting Enzyme AntagonistsAngiotensin-Converting Enzyme InhibitorsAnimal ModelAnimal Models and Related StudiesAnimalsAntibiotic AgentsAntibiotic DrugsAntibioticsAnticholesteremic AgentsAnticholesteremic DrugsAnticholesteremicsArkansasAtomic WarfareBiologicalBiological MarkersBlood PlasmaBody SystemBody TissuesBone MarrowBone Marrow Reticuloendothelial SystemCancersCardiacCardiovascularCardiovascular Body SystemCardiovascular Organ SystemCardiovascular PhysiologyCardiovascular systemCholesterol InhibitorsCholesterol-Lowering DrugsCholesterol-Lowering agentsCollaborationsColony Stimulating Factor 3Common Rat StrainsDataDevelopmentDevicesDoseDose RateDrugsDysfunctionEarly treatmentElectronsEnsureExposure toFDA approvedFemaleFibrosis in the heartFibrosis in the myocardiumFibrosis within the heartFibrosis within the myocardiumFibrotic myocardiumFunctional disorderGamma RadiationGamma RaysGeneral PopulationGeneral PublicGeneral RadiologyGranulocyte Colony-Stimulating FactorHeartHeart InjuriesHeart VascularIndividualInjuryInterventionIntestinalIntestinesIonizing Electromagnetic RadiationIonizing radiationKininase II AntagonistsKininase II InhibitorsLightLipidsLiquid substanceLisinoprilMalignant NeoplasmsMalignant TumorMeasuresMedicalMedicationMiscellaneous AntibioticModelingMsecNegative Beta ParticleNegatronsNeutronsNuclearNuclear WarfareOrganOrgan SystemPathogenesisPathway interactionsPerformancePharmaceutical PreparationsPhotoradiationPhysiopathologyPlasmaPlasma SerumPluripoietinPolypharmacyPrinivilProteinsPublic HealthRadiationRadiation DoseRadiation Dose UnitRadiation FibrosisRadiation InjuriesRadiation exposureRadiation-Ionizing TotalRadiologyRadiology SpecialtyRatRats MammalsRattusResearchResearch SpecimenReticuloendothelial System, Serum, PlasmaRiskRoentgen RaysSamplingScienceSimvastatinSpecimenStructureSurvivorsSynvinolinTerrorismTestingTimeTissuesUniversitiesX-RadiationX-Ray RadiationX-rayXrayZestrilactive followupanti-cholesterol agentsanti-cholesterol drugsantihypercholesterolemic agentbio-markersbiologicbiologic markerbiomarkerbiomarker arraybiomarker panelbowelcardiac fibrosiscardiac functioncardiac injurycardiovascular effectscardiovascular functioncardiovascular injurycholesterol biosynthesiscirculatory systemclinical implementationcohortconventional dosageconventional dosingcoronary fibrosisdesigndesigningdevelopmentaldosimetrydrinking waterdrug/agentearly therapyefficacy testingexperiencefeasibility testingfibrotic heartfluidfollow upfollow-upfollowed upfollowupfunction of the heartgranulocyte colony stimulating factorheart fibrosisheart functioninjuriesinjury to organsinjury to the vasculatureionizing outputirradiationirradiation injuryliquidmalemalignancymarker panelmillisecondminimally invasivemodel of animalmultiomicsmultiple omicsmyocardial fibrosisneoplasm/cancernuclear attackorgan injurypanomicspathophysiologypathwayperformance testspharmacologicpre-clinicalpreclinicalpredictive assaypredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpredictive testprogramsradiation countermeasureradiation induced fibrosisradiation mitigationradiation mitigatorradiological countermeasureradiological mitigationradiological mitigatorradiomitigationradiomitigatorspectral energyspectrum energystandard of caresubcutaneoussubdermalsynergismterrorist attacktraditional dosagetraditional dosingvascular injuryγ-Radiationγ-Ray♀♂
Description preview
PROJECT 3 SUMMARY/ABSTRACT
The general population continues to be at risk of exposure to ionizing radiation because of radiological
terrorism, including the detonation of improvised nuclear devices (IND) with an increased chance of radiation
injuries and cancer. Hence, the development of radiation mitigators is critical to ensure public health.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click